Newsfeeds - Spark Newswire

3 minute read

Adaptimmune Enters Collaboration With Genentech To ‘Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies’; Co. To Receive $150M Upfront Payment, $150M Over Next Five Years And Potential Milestones Up To $3B

Today, 8:54 AM

- Combining both companies' cell therapy leadership and expertise, the collaboration covers the research and development of "off-the-shelf" cell therapies for up to five shared cancer targets and the

ADAP

1 minute read

Legal
News

Adaptimmune Limited Granted U.S. Patent Titled ‘T cell receptors’

By Benzinga Newsdesk

Today, 8:54 AM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5560&f=G&l=50&d=PTXT&p=112&S1=20210810&OS=20210810&RS=20210810

ADAP

1 minute read

SVB Leerink Maintains Market Perform on Adaptimmune Therapeutics, Lowers Price Target to $5

By Benzinga Newsdesk

Today, 8:54 AM

SVB Leerink analyst Jonathan Chang maintains Adaptimmune Therapeutics (NASDAQ:ADAP) with a Market Perform and lowers the price target from $6 to $5.

ADAP

1 minute read

Adaptimmune Therapeutics Q2 EPS $(0.40) Down From $(0.04) YoY, Sales $3.10M Beat $1.36M Estimate

By Benzinga Newsdesk

Today, 8:54 AM

Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.40) per share. This is a 900 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales

ADAP

14 minute read

Earnings Scheduled For August 9, 2021

By Benzinga Insights

Today, 8:54 AM

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.

ACM

7 minute read

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight

By Shanthi Rexaline

Today, 8:54 AM

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.

ABCL